Discover one of our 28 local entrepreneurial communities »
Be the first to know as we launch in new countries and markets around the globe.
Interested in bringing MIT Technology Review to your local market?
Unsupported browser: Your browser does not meet modern web standards. See how it scores »
Engineering a patient’s own immune cells to resist HIV could eliminate the need for lifelong antiretroviral therapies.
By delivering gene therapies to patients before they go blind, doctors may be able to prevent the loss of many important light-detecting cells.
Are we prepared to know the genetic flaws of the unborn?
A Boston startup wants to create precise genome-editing treatments that can address more types of disease than previous gene therapy methods.
Several gene therapies are or will soon be in late-stage human trials. One of them could be the first to get FDA approval for sale in the U.S.
From millions of random mutations, scientists identify a virus that could make gene therapy for inherited retinal diseases safer and more effective.
New partnerships could help bring a novel class of biopharmaceutical to patients.
Patients can turn off an experimental treatment if side effects get too bad.
In 2012, genomics tiptoed into the doctor’s office, gene therapy rose again, and man and machine united.
Regulatory approval of a gene therapy treatment in Europe could spark broader patient access to the technology.